Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
@Sayf - that's my point, doesn't matter whether ODX manufacture Mologic test, or Avacta test, or both - all will be good for ODX. (the market in the UK alone is bigger than ODX, BBI and Abington can manufacture Mologic & Avacta tests, and the world is so much bigger).
Point you missed is that ODX have been in discussions with AVCT about manufacturing their test (fact) - so there must be an AVCT test to manufacture otherwise why talk? so why emphasize one rather than the other?
You then say in your next post
"Another question for you, why would Mologic put out an inaccurate test fully aware of the above? That’s actually from the Mologic site"
What do you mean by 'inaccurate'. Is the Mologic test in technology transfer? Is it in clinical trials? Do you know specificity and sensitivity?
I think your answers are you don't know, but you post as if you are aware of the facts.
I'm invested here, in AVCT, NYCT, SYNG & TILS (Last not strictly a covid stock).
I want them all to do well, but get a bit frustrated when people post implying confident facts when they are nothing more than opinions.
@Safy, you state that "We have links to Mologic, could assist AVCT but I don’t think that’s any time soon".
Do you have any facts that you are prepared to share as to why ODX won't be assisting AVCT anytime soon, or is that just board conjecture/waffle?
Did Boris Johnson say Abbott ?
Touche
At the end of the paper, reference (1) states:
[1] Carter LJ, Garner LV, Smoot JW, Li Y, Zhou Q, Saveson CJ, Sasso JM, Gregg AC, Soares DJ, Beskid TR, Jervey SR, Liu C
(2020). ACS Cent. Sci. 6: 591-605.
Notice 2020 in there, 5 years after 2015?
Hi Korda, the test is Medusa19 antibody19 not AVCT antibody (AVCT are antigen), but I take your point about gov not seeming to show interest. However, not sure how/whether Medusa19 are approaching the gov - think ODX & partners will be using a more formal & acceptable approach as for as the gov are concerned.
Why do you come onto the Avacta board and post your provocative post? should I post my previous post on the ODX board? do you want to start all that rubbish again? Maybe you need to grow up.
@Merchantbanker, are you ramping on the ODX board to con the other investors before you have sold out? I notice earlier on the ODX board that you were ramping the ODX antibody test as a mass screening tool, but we all know (at least outside the ODX board) that you can't use an antibody test for regular mass screening to stop the virus - what about early (pre antibody), asymptomatic spreaders?
Hello Daveb1, I hope that you are an honest investor and not a deramper, but this is the second post after you said you would not be posting anymore. Hopefully you are just naive in terms of research, and we owe you an apology if this is the case. However, if you are not an honest investor then ..... off. Honestly, on the internet, can't tell either way.
@Craig24 & @Falesta - apologies if I've stepped over the boundary!
I think the title of the post & the lateness on Saturday night set my thought pattern.
@Falesta apologies if this was an honest attempt to share information on this board.
1st post on Avacta. Late on Saturday night - normally means deramper. Normally follwed by 'sorry if posted here before'
What motivates them to do this? (I expect a response of 'been here since 1800 and have 2m shares')
What is your point Falesta? so, apparently, paper pregnancy tests can cost as little as 15p (in theory). How is that relevant to this board?
I should add I said 20mil produced a month - which I think is achievable from our current partners with what I understand as easily achievable increases in production volumes. But what if we find new manufacturing volume for the UK - maybe trebling to 60mil a month (which is only one test a month for the UK population - 1/30th of the goal) that would add, if continued for a year, over£900m to the company's profits at £2 a test, and c£4 to the share price (not in terms of p/e, but purely in terms of cash on the balance sheet) - I guess we would be bought out before then by one of the big pharmas.
Point is that this is very difficult to value, but the risks seem very low.